Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Income: 2016-2024

Historic Operating Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Dec 2024 value amounting to -$338.9 million.

  • Crinetics Pharmaceuticals' Operating Income fell 62.40% to -$142.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$477.8 million, marking a year-over-year decrease of 55.77%. This contributed to the annual value of -$338.9 million for FY2024, which is 52.22% down from last year.
  • Crinetics Pharmaceuticals' Operating Income amounted to -$338.9 million in FY2024, which was down 52.22% from -$222.6 million recorded in FY2023.
  • Crinetics Pharmaceuticals' Operating Income's 5-year high stood at -$75.0 million during FY2020, with a 5-year trough of -$338.9 million in FY2024.
  • Moreover, its 3-year median value for Operating Income was -$222.6 million (2023), whereas its average is -$243.1 million.
  • Data for Crinetics Pharmaceuticals' Operating Income shows a maximum YoY slumped of 55.88% (in 2022) over the last 5 years.
  • Crinetics Pharmaceuticals' Operating Income (Yearly) stood at -$75.0 million in 2020, then plummeted by 43.69% to -$107.7 million in 2021, then slumped by 55.88% to -$167.9 million in 2022, then tumbled by 32.60% to -$222.6 million in 2023, then slumped by 52.22% to -$338.9 million in 2024.